Stenting for cholangiocarcinoma may be only a palliative treatment modality, when surgical management is no longer possible, and the only way to reduce jaundice, control infection, and improve patients’ clinical symptoms and quality of life is by placing stents, which does not significantly prolong patients’ survival. These patients are likely to die within 3-6 months, and some of them may survive for less than 1 month. Of course, for some patients with bile duct cancer, due to the severe jaundice symptoms, it is also possible to first reduce jaundice and lower bilirubin levels by placing stents, thus further increasing intraoperative and postoperative safety. After reducing the jaundice to a reasonable level, the tumor is then removed through radical surgery and postoperative comprehensive treatment is given. At this point, patients may have a relatively good survival period, and some patients may even survive for more than 3 or even 5 years. However, it should be noted that cholangiocarcinoma itself is a highly malignant tumor of the digestive system, and when jaundice symptoms appear, it is likely to be in the middle and late stages of the disease, so the overall prognosis is poor.